Browse drugs

…re on adalimumab, 39 (32.8%) on secukinumab, and five (4.2%) on bimekizumab. Among those on adalimumab, 96.0% follow a weekly regimen, whil…

… lack of efficacy, six patient decision, five pregnancy) and 37 ixekizumab patients (seven toxicity, 17 loss of response, one patient deci…

…ary 2025) was conducted including all PsA patients treated with secukinumab monotherapy.Data were collected from electronic records and the…

…ey role in HS pathophysiology, making IL-17 inhibitors, such as secukinumab, a therapeutic option.Aim and Objectives To assess the effectiv…

…al bone damage over 48 months in patients with PsA treated with secukinumab, suggesting that anti-IL-17A therapy induces sustained osteopro…

…onders (–2.2).Conclusion No statistically significant effect of secukinumab dose escalation on reducing MRI-detected inflammation was obser…

…which are effective but increase the risk of tuberculosis (TB). Secukinumab, an interleukin-17A inhibitor, has not been linked to TB reacti…

…ving partial or continuous reinforcement schedules with reduced secukinumab doses combined with a distinctive gustatory stimulus. Primary o…

…arthritis was the most frequent diagnosis (30%).Drugs involved: adalimumab (35%), etanercept (25%), certolizumab (8%), belimumab (6%), ixe…

…ntre study in SH adult patients receiving biological treatment (adalimumab, secukinumab or bimekizumab) at a general hospital (March-June …

…ted. To ensure continued psoriasis control and treatment of UC, risankizumab, a selective IL-23 inhibitor, was administered at the standard …

…a man in his 40s with psoriatic arthritis, well controlled with secukinumab, who developed chronic bilateral knee effusion and soft, non-te…